Viatris News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

18.12.24	Viatris Reports Phase 2b CARE Study Data For Cenerimod - Quick Facts (RTTNews)
07.11.24	Viatris Inc. Q3 Profit Decreases, But Beats Estimates (RTTNews)
09.10.24	Viatris: EFFEXOR Meets Primary And All Secondary Efficacy Endpoints In Japan - Quick Facts (RTTNews)
08.08.24	Viatris Sees 2024 Revenue Growth Of Approx. 2% On Divestiture-adj. Operational Basis - Update (RTTNews)
08.08.24	Viatris Inc. Q2 Earnings Summary (RTTNews)
02.07.24	Viatris: Mylan No Longer Subject Of Generic Drug Industry Antitrust Investigation (RTTNews)
26.06.24	European Commission Approves Proposed Acquisition Of Viatris By Cooper Consumer Health (RTTNews)
09.05.24	Viatris Inc. Q1 Profit Drops, Inline With Estimates (RTTNews)
15.04.24	Viatris Announces Launch Of Bioequivalent Generic For Copaxone In Canada - Quick Facts (RTTNews)
01.04.24	Ocuphire Announces Commercial Launch Of Ryzumvi In U.S. By Its Partner Viatris (RTTNews)
01.04.24	Viatris Announces US Commercial Launch Of RYZUMVl 0.75% (RTTNews)
28.02.24	Viatris Guides FY24 In Line With Estimates - Update (RTTNews)
28.02.24	Viatris Inc. Q4 Earnings Summary (RTTNews)
28.02.24	Biotech Stocks Facing FDA Decision In March 2024 (RTTNews)
28.02.24	Viatris, Idorsia Announce Global Research And Development Collaboration (RTTNews)
21.12.23	Viatris to Participate in 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
15.12.23	Viatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora "Doretta" Mistras as Chief Financial Officer, Effective March 1, 2024, and Philippe M... (PR Newswire)
15.12.23	Viatris Shareholders Re-elect All Nominated Directors and Approve All Voting Matters at Annual Meeting of Shareholders (PR Newswire)
14.11.23	Viatris to Participate in the Jefferies London Healthcare Conference (PR Newswire)
13.11.23	Viatris, Theravance Report Positive Top-line Results From Phase III Trial For YUPELRI In China (RTTNews)
13.11.23	Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) (PR Newswire)
07.11.23	Viatris Inc. Profit Declines In Q3 (RTTNews)
30.10.23	Viatris to Host Webinar: The Power of Partnership to Address Antimicrobial Resistance (PR Newswire)
23.10.23	Viatris Named to Forbes' Annual List of the World's Best Employers for the Third Year in a Row (PR Newswire)
21.10.23	Viatris President Rajiv Malik To Retire In April 2024 (RTTNews)
20.10.23	Rajiv Malik to Retire as President of Viatris Effective April 1, 2024 (PR Newswire)
18.10.23	Viatris Named to 3BL's 100 Best Corporate Citizens of 2023 Ranking (PR Newswire)
10.10.23	Viatris to Release Third Quarter 2023 Financial Results on November 7, 2023 (PR Newswire)
01.10.23	Viatris Announces Agreements on Remaining Planned Divestitures; Upon Closing Would Achieve its Original Total Target of a Multiple Above 12x on 2022 Estimated Adjusted EBITDA (PR Newswire)
27.09.23	Viatris, Ocuphire Pharma Announce FDA Approval Of RYZUMVl - Quick Facts (RTTNews)
27.09.23	Viatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Ago... (PR Newswire)
12.09.23	Viatris Named to TIME's World's Best Companies 2023 List (PR Newswire)
05.09.23	Viatris: FDA Issues Tentative Approval For Single Tablet Regimen In HIV Treatment For Children (RTTNews)
05.09.23	Viatris Announces U.S. FDA Tentative Approval of a Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), a Once-daily Treatment for Children Living with HIV (PR Newswire)
07.08.23	Viatris Reaffirms FY23 Revenue Outlook, Declares Dividend - Update (RTTNews)
07.08.23	Viatris, Mapi Pharma: FDA Accepts For Review NDA For GA Depot To Treat RMS (RTTNews)
07.08.23	Viatris Inc. Q2 Profit Drops (RTTNews)
07.08.23	Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis (PR Newswire)
31.07.23	Viatris Announces Launch of Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the First FDA-Approved Generic Version of Symbicort® for People with Asthma and Chronic Obstr... (PR Newswire)
07.07.23	ROSEN, NATIONAL TRIAL LAWYERS, Encourages Viatris Inc. Investors to Secure Counsel Before Important July 14 Deadline in Securities Class Action - VTRS (PR Newswire)
01.07.23	ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Viatris Inc. Investors to Secure Counsel Before Important July 14 Deadline in Securities Class Action - VTRS (PR Newswire)
28.06.23	Viatris to Report Second Quarter 2023 Financial Results on August 7, 2023 (PR Newswire)
20.06.23	ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Viatris Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - VTRS (PR Newswire)
14.06.23	ROSEN, LEADING INVESTOR COUNSEL, Encourages Viatris Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - VTRS (PR Newswire)
08.06.23	ROSEN, SKILLED INVESTOR COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS (PR Newswire)
01.06.23	VTRS INVESTOR NEWS: TOP RANKED ROSEN LAW FIRM Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS (PR Newswire)
30.05.23	Viatris Named to USA Today's Inaugural List of America's Climate Leaders 2023 (PR Newswire)
25.05.23	ROSEN, A RESPECTED AND LEADING FIRM, Encourages Viatris Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - VTRS (PR Newswire)
22.05.23	Robert J. Coury to Transition from Executive Chairman of Viatris to Chairman Emeritus and Senior Strategic Advisor to the Board and Management at the End of the Year (PR Newswire)
22.05.23	Viatris Announces Appointment of Leo Groothuis to Company's Board of Directors (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

24.12.24		Aufschläge in New York: S&P 500 verbucht zum Handelsende Zuschläge
24.12.24		Optimismus in New York: So entwickelt sich der S&P 500 am Nachmittag
09.12.24		S&P 500-Titel Viatris-Aktie: So hoch ist die Dividende von Viatris
07.11.24		Pluszeichen in New York: S&P 500 zum Handelsende auf grünem Terrain
07.11.24		Börse New York in Grün: Am Donnerstagnachmittag Gewinne im S&P 500
07.11.24		S&P 500 aktuell: S&P 500 präsentiert sich am Mittag fester
07.11.24		Gute Stimmung in New York: S&P 500 zum Handelsstart im Aufwind
20.09.24		Schwacher Handel in New York: S&P 500 verbucht schlussendlich Verluste

24.12.24

Aufschläge in New York: S&P 500 verbucht zum Handelsende Zuschläge

24.12.24

Optimismus in New York: So entwickelt sich der S&P 500 am Nachmittag

09.12.24

S&P 500-Titel Viatris-Aktie: So hoch ist die Dividende von Viatris

07.11.24

Pluszeichen in New York: S&P 500 zum Handelsende auf grünem Terrain

07.11.24

Börse New York in Grün: Am Donnerstagnachmittag Gewinne im S&P 500

07.11.24

S&P 500 aktuell: S&P 500 präsentiert sich am Mittag fester

07.11.24

Gute Stimmung in New York: S&P 500 zum Handelsstart im Aufwind

20.09.24

Schwacher Handel in New York: S&P 500 verbucht schlussendlich Verluste

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Kuehne+Nagel Int	207.70	1.32 %	K V
Lonza Grp	537.60	0.98 %	K V
UBS Group	27.33	0.96 %	K V
Logitech Intl	74.88	0.78 %	K V
Part Grp Hldg	1’221.50	0.29 %	K V
Swiss Life Hldg	694.80	-0.26 %	K V
Holcim	87.14	-0.27 %	K V
CieFinRichemont	135.60	-0.37 %	K V
Swiss Re	129.65	-0.54 %	K V
Zurich Insur Gr	535.40	-0.67 %	K V

Nachrichten zu Viatris Inc Registered Shs

Aktien Top/Flop

Viatris Peer Group Nachrichten

Meistgelesene Nachrichten